Ablation Registry (Combined Gastric Mucosal Ablation With Endoscopic Sleeve Gastroplasty for Weight Loss)

Last updated: May 20, 2024
Sponsor: True You Weight Loss
Overall Status: Active - Recruiting

Phase

N/A

Condition

Obesity

Weight Loss

Diabetes Prevention

Treatment

Combined gastric mucosal ablation with endoscopic sleeve gastroplasty

Clinical Study ID

NCT06420700
RGT-001
  • Ages 18-65
  • All Genders

Study Summary

The purpose of this study is to construct a multi-site, prospective registry to evaluate the clinical outcomes of patients who have undergone combined gastric mucosal ablation with endoscopic sleeve gastroplasty at True You Weight Loss.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Age ≥ 18 years and ≤ 65 years old

  2. BMI ≥ 28 and ≤55 kg/m²

  3. Willingness to comply with the substantial lifelong dietary restrictions required bythe procedure.

  4. Ability to give informed consent

  5. Women of childbearing potential (i.e., not post-menopausal or surgically sterilized)must agree to use adequate birth control methods.

  6. Those who plan to receive the gastric mucosal ablation with ESG procedure at TrueYou Weight Loss regardless of the research

Exclusion

Exclusion Criteria:

  1. Patients that do not meet eligibility requirements for the study as per thePrincipal Investigator's standard selection criteria

  2. Active psychological issues preventing participation in a life-style modificationprogram as determined by a psychologist.

  3. Patients who are pregnant or breast-feeding.

  4. Patients currently taking weight-loss medications or other therapies for weight losswithin the prior 6 months.

  5. Eating disorders including night eating syndrome (NES), bulimia, binge eatingdisorder, or compulsive overeating.

  6. At the discretion of the PI for subject safety

Study Design

Total Participants: 100
Treatment Group(s): 1
Primary Treatment: Combined gastric mucosal ablation with endoscopic sleeve gastroplasty
Phase:
Study Start date:
January 31, 2024
Estimated Completion Date:
January 31, 2028

Study Description

Obesity is a chronic disease state driven by the imbalance of caloric intake and expenditure and mediated by multiple central and peripheral pathways that may serve as targets for therapeutic interventions. The endoscopic sleeve gastroplasty (ESG) is a per oral gastric remodeling technique that employs full-thickness suturing to imbricate the stomach along the greater curvature to achieve a restricted, sleeve-like configuration. While the ESG recapitulates the configuration of a gastric sleeve, it has not yet been shown to achieve as robust weight loss outcomes compared to the laparoscopic sleeve gastrectomy (LSG). A major difference between ESG and LSG is that the former does not involve the gastric fundus. The proximal stomach, and the fundus in particular, produces ghrelin, the only known orexigenic hormone, which has been linked to increased calorie intake and weight gain. Studies have observed reduced levels of ghrelin along multiple timepoints following LSG and this has been attributed to targeting of the fundus, as bariatric surgeries that did not involve the fundus did not see a decrease in circulating plasma ghrelin. In contrast, in a small comparative study of ESG and LSG, patients who had undergone ESG did not show any decrease in fasting ghrelin levels, ostensibly due to fundic-sparing. In a preliminary, first-in-human study conducted by True You Weight Loss (ABLATE Weight), gastric fundus ablation via hybrid argon plasma coagulation was followed sequentially by ESG after 6 months. In this 10-patient study, fundus ablation was performed safely in all cases and without serious adverse events. A subsequent first-in-human study (ABLATE WEIGHT 2) further investigated gastric fundus ablation in a single-stage approach by combining fundus ablation and ESG during the same endoscopic session. Preliminary data revealed enhanced clinical effectiveness for the single-stage approach when compared to traditional endoscopic sleeve gastroplasty while maintaining a clinically feasible safety profile. By constructing a multi-site, prospective registry, the investigators aim to longitudinally collect and assess the clinical outcomes and characteristics of patients undergoing combined gastric mucosal ablation with endoscopic sleeve gastroplasty (ESG) at True You Weight Loss.

Connect with a study center

  • True You Weight Loss

    Atlanta, Georgia 30342
    United States

    Active - Recruiting

  • True You Weight Loss

    Cary, North Carolina 27513
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.